Panbela Therapeutics, Inc.: Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Aden

MINNEAPOLIS, Jan. 19, 2023). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to SBP-101. "We are pleased to receive notice that the European Commission has adopted

Related Keywords

United States ,Jenniferk Simpson ,Tammy Groene ,Committee For Orphan Medicinal Products ,Panbela Therapeutics Inc ,European Union ,European Commission ,Nasdaq Stock Market ,Drug Administration ,Orphan Medicinal Products ,Chief Executive Officer ,Orphan Medicinal ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Panbela ,Herapeutics ,Nnounces ,Adoption ,Commission ,Implementing ,Decision ,Rom ,Orphan ,Resignation ,Vospemin ,Combination ,Gemcitabine ,Paclitaxel ,Patients ,Metastatic ,Pancreatic ,Ductal ,D ,